Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07357220 | A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases | PHASE1 | NOT YET_RECRUITING | 72 | — | — | Mar 2, 2026 | Feb 28, 2028 | Jan 21, 2026 | 1 | China |
Number of participants who meet the criteria of dose-limiting toxicities (DLTs) in DLT observation period
Number of participants experiencing adverse events (AEs) and severity, graded according to CTCAE v5.0
Proportion of participants with complete response (CR) or partial response (PR), as assessed by RECIST version 1.1
| Arm | Type | Description |
|---|---|---|
| Cohort A (VG2025+AK112) | EXPERIMENTAL | VG2025 (Recommended Phase II Dose), Intratumoral Injection, Q4W + AK112 (20mg/kg), ivgtt, Q2W. |
| Cohort B (AK112) | EXPERIMENTAL | AK112 (20mg/kg), ivgtt, Q2W |
| Name | Type | Description |
|---|---|---|
| VG2025 | BIOLOGICAL | Recommended Phase II Dose, Intratumoral Injection, Q4W |
| AK112 | DRUG | 20mg/kg, ivgtt, Q2W |
Inclusion Criteria: 1. Signed informed consent 2. Age≥18 years and ≤ 75 years 3. Histologically or cytologically confirmed unresectable colorectal cancer with liver metastases; adenocarcinoma type 4. Disease progression after first- or second-line standard therapy 5. At least one measurable disease...